MedPath

DEvice-Detected CArdiac Tachyarrhythmic Events and Sleep-disordered Breathing (DEDiCATES)

Conditions
Cardiac Event
Sleep Disorder
Cardiac Arrythmias
Cardiac Implantable Electronic Device
Interventions
Diagnostic Test: Device interrogation
Registration Number
NCT03614377
Lead Sponsor
Samsung Medical Center
Brief Summary

This prospective multicenter registry study aims to determine whether device-detected sleep-disordered breathing events are associated increased risk of cardiac arrhythmias or other cardiovascular outcomes.

Detailed Description

The prevalence of SDB high in patients with cardiac implantable electronic device (CIED). Recently, device-detected SDB events showed a correlation with sleep-disordered breathing (SDB) diagnosed by polysomnography. Thus, CIED will facilitate early detection and monitoring of SDB in patients with CIEDs. Few studies investigated prognostic value of CIED-detected SDB in risk of cardiovascular events. Therefore, the primary aim is to determine whether device-detected SDB are associated with increased risk of cardiac arrhythmias or other cardiovascular morbidities using a prospective multicenter registry.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
600
Inclusion Criteria
  • age ≥ 19years
  • CHA2DS2VASc score ≥ 1 in male or ≥ 2 in female
Read More
Exclusion Criteria
  • CIED without atrial lead
  • persistent or permanent atrial fibrillation (AF) or flutter
  • history of catheter of surgical ablation of AF
  • valvular steno-insufficiency more than moderate degree
  • chronic obstructive pulmonary disease
  • under current treatment for sleep-disordered breathing
  • life expectancy < 1year
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Patients with low burden of sleep-disordered breathingDevice interrogation-
Patients with high burden of sleep-disordered breathingDevice interrogation-
Primary Outcome Measures
NameTimeMethod
Number of participants with atrial fibrillationfrom enrollment to last follow-up (2 years)

cardiac implantable electronic device-detected or clinical atrial fibrillation

Secondary Outcome Measures
NameTimeMethod
Number of participants with ventricular arrhythmiafrom enrollment to last follow-up (2 years)

cardiac implantable electronic device-detected or clinical ventricular arrhythmia

Number of participants with complications associated with atrial fibrillationfrom enrollment to last follow-up (2 years)

thromboembolic events, heart failure, ablation therapy for atrial fibrillation

Trial Locations

Locations (14)

Chungbuk National University Hospital

🇰🇷

Chungju, Korea, Republic of

Samsung Changwon Medical Center

🇰🇷

Changwon, Korea, Republic of

Yeongnam University Medical Center

🇰🇷

Daegu, Korea, Republic of

Daegu Catholic University Medical Center

🇰🇷

Daegu, Korea, Republic of

Chonnam National University Hospital

🇰🇷

Gwangju, Korea, Republic of

Chungnam National University Hospital

🇰🇷

Daejeon, Korea, Republic of

Sejong General Hospital

🇰🇷

Sejong, Korea, Republic of

Eulji University Hospital

🇰🇷

Daejeon, Korea, Republic of

Asan Medical Center

🇰🇷

Seoul, Korea, Republic of

Korea University Anam Hospital

🇰🇷

Seoul, Korea, Republic of

Seoul National University Bundang Hospital

🇰🇷

Seoul, Korea, Republic of

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

The Catholic University of Korea, Seoul St. Mary's Hospital

🇰🇷

Seoul, Korea, Republic of

Yonsei University Health System, Severance Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath